Blischak Matthew P. 4/A
4/A · Finch Therapeutics Group, Inc. · Filed Jun 23, 2023
Insider Transaction Report
Form 4/AAmended
Blischak Matthew P.
Chief Executive Officer
Transactions
- Award
Stock Option (right to buy)
2023-06-09+962,899→ 962,899 totalExercise: $0.27Exp: 2033-06-08→ Common Stock (962,899 underlying)
Footnotes (2)
- [F1]On June 9, 2023, the Reporting Person filed a Form 4, which, due to administrative error, inadvertently reported that the reported stock options were granted on June 8, 2023 with a strike price of $0.285, the closing price of the issuer's common stock on such date, and expiration date of June 7, 2033. In fact, as reported in this amendment, the reported stock options were granted on June 9, 2023 with a strike price of $0.271, the closing price of the issuer's common stock on such date, and expiration date of June 8, 2033.
- [F2]Twenty-five percent (25%) of the shares subject to this option shall vest on June 9, 2024, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service as of each such date.